Review of drug interactions with telaprevir and antiretrovirals

Antiviral Therapy

Volumn 18, Issue 4, 2013, Pages 553-560

  Van Heeswijk, Rolf P G ^a   Beumont, Maria ^a   Kauffman, Robert S ^b   Garg, Varun ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIGOXIN; EFAVIRENZ; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; RITONAVIR; TELAPREVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

AREA UNDER THE CURVE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; OLIGOPEPTIDES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 84879845284     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2527     Document Type: Review

References (44)

1. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436:953-960.
2. Brown RS, Jr., Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl 2003; 9:S10-S13.
3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20:1-16.
4. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20:17-35.
5. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9.
6. Chen TY, Ding EL, Seage GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIVinfected person is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-1615.
7. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al. Risk of developing specific AIDS defining illnesses in patients co-infected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009; 49:612-622.
8. Kovacz A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010; 201:823-834.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 10 January 2011; pp. 1-166.
10. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV infected individuals and the impact of HIV in the era of the highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991.
11. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007; 14:239-248.
12. Incivo (telaprevir). Summary of product characteristics. (Updated 19 September 2011. Accessed 21 May 2012.) Available from http://www.ema.europa.eu/ ema/pages/includes/document/open-document. jsp?webContentId=WC500115529
13. Incivek (telaprevir). FDA prescribing information. (Updated April 2013. Accessed 1 November 2012.) Available from http://pi.vrtx.com/files/uspi- telaprevir.pdf
14. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6:3-16.
15. Garg V, Kauffman RS, Beaumont M, van Heeswijk RPG. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther; 2012; 17:1211-1221.
16. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012; 52:1566-1573.
17. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
18. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
19. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
20. Gordon SC, Muir AJ, Garg V, Henshaw J. Exposureresponse relationships in telaprevir combination therapy in treatment-naive genotype 1 chronic HCV patients. J Hepatol 2012; 56 Suppl 2:S440.
21. Garg V, Luo X, McNair L, van Heeswijk R, Kauffman RS. The effect of low-dose ritonavir on the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 629.
22. Vishnuvardhan D, von Moltke LL, Richtert C, Greenblat DJ. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 2003; 17:1092-1094.
23. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63:769-802.
24. Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 19.
25. VictrelisTM (boceprevir) capsules. FDA prescribing information. (Updated May 2011. Accessed 22 February 2012.) Available from http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/202258lbl.pdf
26. Hulskotte E, Feng HP, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir and darunavir. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA, 2012. Abstract 77IL.B.
27. Van Heeswijk R, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. European Association for the Study of the Liver. 30 March-3 April 2011, Berlin, Germany. Abstract 1244.
28. Chakilam A, Chavan A, Smith G, Lachau-Durand S, Garg V. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and ritonavir or warfarin. Rev Antiviral Ther Infectious Dis 2011; 6:22.
29. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-835.
30. Sadler BM, Gillotin C, Lou Y, Stein DS. In vivo effect of a1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45:852-856.
31. Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46:739-756.
32. Barrail-Tran A, Mentre F, Cosson C, et al. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 study. Antimicrob Agents Chemother 2010; 54:614-619.
33. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498-3504.
34. Truvada (emtricitabine/tenofovir disoproxil fumarate). Summary of product characteristics. (Updated 24 June 2013. Accessed 27 June 2013.) Available from http://www. medicines.org.uk/EMC/medicine/15826/SPC/Truvada+filmcoated+ tablets
35. Van Heeswijk R, Gysen V, Boogaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. Interscience Conference on Antimicrobial Agents and Chemotherapy. 25 October 2008, Washington, DC, USA. Abstract A-966.
36. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50:3297-3304.
37. Sustiva (efavirenz). Summary of product characteristics. (Updated 25 June 2013. Accessed 27 June 2013.) Available from http://www.medicines.org.uk/emc/ medicine/11284/SPC/Sustiva+600+mg+Film-Coated+Tablet.s.
38. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013; 75:431-439.
39. Kakuda TN, Schöller Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and nonantiretroviral drugs. Clin Pharmacokinet 2011; 50:25-39.
40. Kakuda TN, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial. 13th International Workshop on Clinical Pharmacology of HIV. 16-18 April 2012, Barcelona, Spain. Abstract 0-18.
41. Crauwels H, Vingerhoets J, Ryian R, Witek J, Anderson D. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther 2012; 17:439-446.
42. Vanveggel S, Buelens A, Crauwels HM, et al. TMC278 25mg once daily has no effect on corrected QT interval in a study in HIV-negative volunteers. 12th European AIDS Clinical Society. 11-14 November 2009, Cologne, Germany. Abstract PE7.1/2.
43. Van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. 17 September 2011, Chicago, IL, USA. Abstract 1738a.
44. Dietrich DT, Soriano V, Sherman KE, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV coinfected patients: a 24-week treatment interim analysis. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 46.